MRNA Stock Recent News

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

'Mad Money' host Jim Cramer looks at today's market winners and losers.

Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA cancer vaccine combined with Merck's (MRK) blockbuster drug Keytruda.

Major U.S. equities made little headway in the session preceding the release of Consumer Price Index (CPI) report for March.

Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.

Moderna shares rose 8% in morning trade on Tuesday after the company's individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.